Taiwan team makes breakthrough in nanoparticle tumor treatment
A research team at the Taipei Medical University announced on April 8, 2016, that it has made a breakthrough in nanoparticle tumor treatment. The team began research in 2007 to study the effectiveness of the CRLX101 cyclodextrin nanoparticle treatment of patients with solid tumorous malignancies. The problem has been insufficient exposure of tumors and high systemic toxicity. It has been hard to measure the amount of nanoparticle entry into the tumor tissue and the amount of nanoparticle misses that damage the surrounding normal tissue. The research team apparently was improve the detector to register the faint fluorescent anti-body signals and quantify the amount of nanoparticle penetration of the tumor tissue which has been difficult to detect using fluorescent dye or electron microscope observation.
CRLX101 is a cyclodextrin polymer conjugate that delivers nanoparticles targeting solid tumorous malignancies. The problem has been insufficient exposure by the tumor and high systemic toxicity and the inability to quantitatively measure the amount of anti-tumor nanoparticle penetration of the tumorous tissue and the amount of peripheral damage to normal tissue. Clinical experiment using nanoparticle anti-tumor treatment such as the CRLX101 will being its third phase and it is hoped that within two to three years, such an anti-tumor drug will be available on the market to treat solid tumors of ovarian and lung cancers.